Search company, investor...

Epitome Biosystems

epitomebiosystems.com

Stage

Acquired | Acquired

About Epitome Biosystems

Epitome Biosystems is developing platform to synthesize kilobase- to megabase-length genetic code, orders of magnitude more rapidly and less expensively than currently available technology

Headquarters Location

100 Beaver Street

Waltham, Massachusetts, 02453,

United States

Missing: Epitome Biosystems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Epitome Biosystems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Epitome Biosystems News

Millipore Purchases Assets Associated With Epitome Biosystems' EpiTag Technology

Jun 10, 2021

2/26/2009 11:48 AM ET Millipore Corp. ( MIL ) on Thursday said that it has purchased the assets associated with Epitome Biosystems' EpiTag technology . The purchase price was not disclosed. Additionally, the acquisition will allow for the future development of other novel profiling technologies. For comments and feedback contact: editorial@rttnews.com

Epitome Biosystems Frequently Asked Questions (FAQ)

  • Where is Epitome Biosystems's headquarters?

    Epitome Biosystems's headquarters is located at 100 Beaver Street, Waltham.

  • What is Epitome Biosystems's latest funding round?

    Epitome Biosystems's latest funding round is Acquired.

  • Who are the investors of Epitome Biosystems?

    Investors of Epitome Biosystems include MilliporeSigma and Flagship Pioneering.

  • Who are Epitome Biosystems's competitors?

    Competitors of Epitome Biosystems include Fusion Antibodies, WaferGen Bio-systems, Evogen, GenTel BioSciences, Incept Biosystems and 11 more.

Compare Epitome Biosystems to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

K
Kelaroo

The KRMS aims to provide their organization with the tools needed to keep the key ingredients of research at their scientists' fingertips. Using the KRMS, researchers as well as stockroom, purchasing and EH&S personnel readily find, request, receive and track all chemical products. Inventory Management Reagent & Chemical Management for Pharma, BioTech, Manufacturers and Integrators (ELN, ERP, LIMS) Genome mining, sequence profiling and optimization Enhance their bioinformatics discovery program with SeqR. SeqR applies machine learning to public and sequence data to generate models with powerful sequence profiling abilities well suited to genome mining, sequence optimization, and SAR analysis.

PrimaDiag Logo
PrimaDiag

PrimaDiag is a start-up developing tools to automate biological processes for diagnostics and research

V
Virmatics

Virmatics is a bioinformatics software company developing efficient, and automated tools for biomedical researchers. Their software aims to give researchers the ability to plan experiments and record, store, and analyze data with unparalleled flexibility. Virmatics has been a member of the incubator since Fall 2004.

N
Narvalus srl

The firm aims to provide powerful tools based on microelectronic technology to scientists involved in basic molecular biology research. Investigating the biological actions of molecules "in vitro" on cultured cells is a fundamental step for drug development and for basic life sciences. Routine techniques for intracellular delivery are high-cost and time-consuming procedures involving the use of a large amount of the candidate molecule and a stochastic interpretation of the results. Thanks to an combination of cell and molecular biology with semiconductor technology the company developed a new technique overcoming these limitations.

Nabsys Logo
Nabsys

Nabsys develops an electronic mapping solution for the analysis of genomic structural information. It offers solutions for genome assembly, structural variation, strain identification, and sample preparation. The company was founded in 2005 and is based in Providence, Rhode Island.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.